PTGS2 and Alzheimer disease: PGE2 then promotes neuroinflammation (Hein and O’Banion, 2009) by increasing the expression of NF-κB and COX-2 (Hsu et al., 2017) and promotes wakefulness by stimulating further glutamate release (Bezzi et al., 1998), both of which contribute to the pathogenesis of AD (Wang et al., 2014; Woodling et al., 2016; Madeira et al., 2018; Sadeghmousavi et al., 2020).